Bioethics News

Stem Cell Factory Opens Door for Trials of Personalized Diabetes Treatment

June 20, 2016

(STAT News) – In patients with type 1 diabetes, the immune system attacks the pancreatic cells that produce insulin, called beta cells. Doctors have for years transplanted beta cells from dead donors into patients, but the supply is insufficient for the millions of people with type 1 diabetes, and patients’ bodies sometimes reject the donor cells. The new program, officially called the Boston Autologous Islet Replacement Program, could provide enough high-quality beta cells needed to treat patients in upcoming clinical trials. And the cells that will be transplanted into these volunteers will be derived from their own blood cells, cutting the risk of rejection.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.